Cathal Friel, CEO of Open Orphan and Nicola Duke looking at charts
Justin Waite
Vox Markets Podcast with Justin Waite
12:40, 11th November 2019

Vox Media Player

DYOR Disclaimer

If you find this podcast useful please give it a rating and review on iTunes by clicking here

Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here:

On today's Vox Markets Podcast: Cathal Friel, CEO of Open Orphan and Nicola Duke looking at charts

Cathal Friel, Chief Executive Officer of Open Orphan (ORPH) FOLLOW discusses the signing of a preferred partner agreement with the Ipsen Group.

Open Orphan plc is a European-focused, rare and orphan drug consulting services platform. The Company intends to roll up a number of pharma services businesses across Europe. Open Orphan has two data driven digital platforms, a Genomic Health Data Platform, which is establishing one of Europe's largest rare disease genomic database and a Virtual Rep platform enabling pharmaceutical companies to engage key opinion leaders and physicians. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.

Nicola Duke

Nicola Duke technical analyst charts:

BitcoinWey Education (WEY) FOLLOW

Xpediator (XPD) FOLLOW

(Interview starts at 9 minutes 1 second)

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles